UroGen Pharma Ltd (URGN)
14.30
+0.04
(+0.28%)
USD |
NASDAQ |
May 03, 16:00
14.29
-0.01
(-0.07%)
Pre-Market: 20:00
UroGen Pharma Debt to Equity Ratio: -1.511 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
December 31, 2023 | -1.511 |
September 30, 2023 | -2.346 |
June 30, 2023 | -0.7101 |
March 31, 2023 | -0.8403 |
December 31, 2022 | -1.092 |
September 30, 2022 | -1.136 |
June 30, 2022 | -1.740 |
March 31, 2022 | -4.146 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
Date | Value |
---|---|
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
December 31, 2017 | 0.00 |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.00 |
March 31, 2017 | |
December 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-4.146
Minimum
Mar 2022
--
Maximum
Jun 2019
-0.7117
Average
--
Median
Jun 2019
Debt to Equity Ratio Benchmarks
Agenus Inc | -0.0805 |
Exelixis Inc | 0.00 |
Geron Corp | 0.2399 |
Protalix BioTherapeutics Inc | 0.6033 |
InfuSystems Holdings Inc | 0.5564 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 178.31M |
Total Liabilities (Quarterly) | 243.52M |
Shareholders Equity (Quarterly) | -65.21M |
Current Ratio | 5.420 |
Net Debt Paydown Yield | -1.10% |